Financhill
Sell
39

SNY Quote, Financials, Valuation and Earnings

Last price:
$48.23
Seasonality move :
-1.1%
Day range:
$48.02 - $48.48
52-week range:
$45.22 - $58.97
Dividend yield:
8.16%
P/E ratio:
24.44x
P/S ratio:
2.28x
P/B ratio:
1.55x
Volume:
637.5K
Avg. volume:
2.5M
1-year change:
-3.02%
Market cap:
$120.9B
Revenue:
$50.3B
EPS (TTM):
$1.97

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SNY
Sanofi SA
$11.5B $0.95 -9.77% 26.36% $63.06
AZN
AstraZeneca PLC
$14.2B $1.10 17.56% 255.34% $90.46
GSK
GSK PLC
$9.8B $0.43 -1.61% 107.8% $45.07
MRNA
Moderna
$1.1B -$2.76 -63.53% -79.68% $74.19
NVAX
Novavax
$90.9M -$0.65 -64.12% -56.12% $16.00
REGN
Regeneron Pharmaceuticals
$3.8B $11.22 9.55% 7.9% $1,053.08
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SNY
Sanofi SA
$48.23 $63.06 $120.9B 24.44x $2.04 8.16% 2.28x
AZN
AstraZeneca PLC
$65.52 $90.46 $203.2B 31.42x $0.50 2.27% 4.00x
GSK
GSK PLC
$33.82 $45.07 $69B 21.99x $0.39 4.62% 1.76x
MRNA
Moderna
$41.58 $74.19 $16B -- $0.00 0% 3.18x
NVAX
Novavax
$8.04 $16.00 $1.3B -- $0.00 0% 1.40x
REGN
Regeneron Pharmaceuticals
$712.33 $1,053.08 $78.3B 17.63x $0.00 0% 5.92x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SNY
Sanofi SA
23.02% -0.165 -- 0.52x
AZN
AstraZeneca PLC
42.54% -0.413 12.47% 0.71x
GSK
GSK PLC
53.41% 0.612 26% 0.52x
MRNA
Moderna
-- -0.054 -- 3.95x
NVAX
Novavax
-47.39% 8.844 8.37% 0.85x
REGN
Regeneron Pharmaceuticals
6.34% 1.263 1.71% 4.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SNY
Sanofi SA
$11.1B $4.5B 4.56% 5.8% 26.62% -$498.5M
AZN
AstraZeneca PLC
$10.5B $2.1B 9.41% 16.72% 16.85% $2B
GSK
GSK PLC
$7.3B $245.9M 8.08% 18.89% 2.75% $1.7B
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
NVAX
Novavax
$23.9M -$134M -- -- -139.74% -$146.8M
REGN
Regeneron Pharmaceuticals
$3.2B $1.2B 16.02% 17.19% 40.5% $1B

Sanofi SA vs. Competitors

  • Which has Higher Returns SNY or AZN?

    AstraZeneca PLC has a net margin of 19.88% compared to Sanofi SA's net margin of 10.54%. Sanofi SA's return on equity of 5.8% beat AstraZeneca PLC's return on equity of 16.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    71.15% $1.24 $101.5B
    AZN
    AstraZeneca PLC
    77.29% $0.46 $70.9B
  • What do Analysts Say About SNY or AZN?

    Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 30.75%. On the other hand AstraZeneca PLC has an analysts' consensus of $90.46 which suggests that it could grow by 34.33%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 1 0
    AZN
    AstraZeneca PLC
    6 1 0
  • Is SNY or AZN More Risky?

    Sanofi SA has a beta of 0.576, which suggesting that the stock is 42.375% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.454%.

  • Which is a Better Dividend Stock SNY or AZN?

    Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.16%. AstraZeneca PLC offers a yield of 2.27% to investors and pays a quarterly dividend of $0.50 per share. Sanofi SA pays 82.48% of its earnings as a dividend. AstraZeneca PLC pays out 75.25% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or AZN?

    Sanofi SA quarterly revenues are $15.6B, which are larger than AstraZeneca PLC quarterly revenues of $13.6B. Sanofi SA's net income of $3.1B is higher than AstraZeneca PLC's net income of $1.4B. Notably, Sanofi SA's price-to-earnings ratio is 24.44x while AstraZeneca PLC's PE ratio is 31.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.28x versus 4.00x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.28x 24.44x $15.6B $3.1B
    AZN
    AstraZeneca PLC
    4.00x 31.42x $13.6B $1.4B
  • Which has Higher Returns SNY or GSK?

    GSK PLC has a net margin of 19.88% compared to Sanofi SA's net margin of -0.72%. Sanofi SA's return on equity of 5.8% beat GSK PLC's return on equity of 18.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    71.15% $1.24 $101.5B
    GSK
    GSK PLC
    70.08% -$0.04 $39.5B
  • What do Analysts Say About SNY or GSK?

    Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 30.75%. On the other hand GSK PLC has an analysts' consensus of $45.07 which suggests that it could grow by 33.28%. Given that GSK PLC has higher upside potential than Sanofi SA, analysts believe GSK PLC is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 1 0
    GSK
    GSK PLC
    2 3 0
  • Is SNY or GSK More Risky?

    Sanofi SA has a beta of 0.576, which suggesting that the stock is 42.375% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.651, suggesting its less volatile than the S&P 500 by 34.884%.

  • Which is a Better Dividend Stock SNY or GSK?

    Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.16%. GSK PLC offers a yield of 4.62% to investors and pays a quarterly dividend of $0.39 per share. Sanofi SA pays 82.48% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or GSK?

    Sanofi SA quarterly revenues are $15.6B, which are larger than GSK PLC quarterly revenues of $10.4B. Sanofi SA's net income of $3.1B is higher than GSK PLC's net income of -$75.5M. Notably, Sanofi SA's price-to-earnings ratio is 24.44x while GSK PLC's PE ratio is 21.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.28x versus 1.76x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.28x 24.44x $15.6B $3.1B
    GSK
    GSK PLC
    1.76x 21.99x $10.4B -$75.5M
  • Which has Higher Returns SNY or MRNA?

    Moderna has a net margin of 19.88% compared to Sanofi SA's net margin of 0.7%. Sanofi SA's return on equity of 5.8% beat Moderna's return on equity of -17.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    71.15% $1.24 $101.5B
    MRNA
    Moderna
    72.29% $0.03 $11.9B
  • What do Analysts Say About SNY or MRNA?

    Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 30.75%. On the other hand Moderna has an analysts' consensus of $74.19 which suggests that it could grow by 78.42%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 1 0
    MRNA
    Moderna
    6 13 1
  • Is SNY or MRNA More Risky?

    Sanofi SA has a beta of 0.576, which suggesting that the stock is 42.375% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

  • Which is a Better Dividend Stock SNY or MRNA?

    Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.16%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or MRNA?

    Sanofi SA quarterly revenues are $15.6B, which are larger than Moderna quarterly revenues of $1.9B. Sanofi SA's net income of $3.1B is higher than Moderna's net income of $13M. Notably, Sanofi SA's price-to-earnings ratio is 24.44x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.28x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.28x 24.44x $15.6B $3.1B
    MRNA
    Moderna
    3.18x -- $1.9B $13M
  • Which has Higher Returns SNY or NVAX?

    Novavax has a net margin of 19.88% compared to Sanofi SA's net margin of -143.53%. Sanofi SA's return on equity of 5.8% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    71.15% $1.24 $101.5B
    NVAX
    Novavax
    28.27% -$0.76 -$357.2M
  • What do Analysts Say About SNY or NVAX?

    Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 30.75%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 99.01%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 1 0
    NVAX
    Novavax
    2 2 0
  • Is SNY or NVAX More Risky?

    Sanofi SA has a beta of 0.576, which suggesting that the stock is 42.375% less volatile than S&P 500. In comparison Novavax has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.083%.

  • Which is a Better Dividend Stock SNY or NVAX?

    Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.16%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or NVAX?

    Sanofi SA quarterly revenues are $15.6B, which are larger than Novavax quarterly revenues of $84.5M. Sanofi SA's net income of $3.1B is higher than Novavax's net income of -$121.3M. Notably, Sanofi SA's price-to-earnings ratio is 24.44x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.28x versus 1.40x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.28x 24.44x $15.6B $3.1B
    NVAX
    Novavax
    1.40x -- $84.5M -$121.3M
  • Which has Higher Returns SNY or REGN?

    Regeneron Pharmaceuticals has a net margin of 19.88% compared to Sanofi SA's net margin of 36.03%. Sanofi SA's return on equity of 5.8% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    71.15% $1.24 $101.5B
    REGN
    Regeneron Pharmaceuticals
    86.8% $11.54 $31.3B
  • What do Analysts Say About SNY or REGN?

    Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 30.75%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.84%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 1 0
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is SNY or REGN More Risky?

    Sanofi SA has a beta of 0.576, which suggesting that the stock is 42.375% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

  • Which is a Better Dividend Stock SNY or REGN?

    Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.16%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or REGN?

    Sanofi SA quarterly revenues are $15.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Sanofi SA's net income of $3.1B is higher than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Sanofi SA's price-to-earnings ratio is 24.44x while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.28x versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.28x 24.44x $15.6B $3.1B
    REGN
    Regeneron Pharmaceuticals
    5.92x 17.63x $3.7B $1.3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is It Time for Costco to Split?
Is It Time for Costco to Split?

Costco’s stock price has experienced enormous growth over the last…

Will FedEx’s Spinoff Boost Its Stock Price?
Will FedEx’s Spinoff Boost Its Stock Price?

In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…

Why Is Buffett Buying Verisign?
Why Is Buffett Buying Verisign?

Warren Buffett has spent 2024 stockpiling cash, even going so…

Stock Ideas

Buy
58
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 41x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
77
FTAI alert for Jan 1

FTAI Aviation [FTAI] is up 13.87% over the past day.

Buy
56
QMCO alert for Jan 1

Quantum [QMCO] is down 13.43% over the past day.

Buy
60
ARQQ alert for Jan 1

Arqit Quantum [ARQQ] is down 10.6% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock